6.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FHTX Giù?
Forum
Previsione
Precedente Chiudi:
$6.47
Aprire:
$6.42
Volume 24 ore:
102.16K
Relative Volume:
0.80
Capitalizzazione di mercato:
$345.04M
Reddito:
$34.16M
Utile/perdita netta:
$-98.43M
Rapporto P/E:
-2.6453
EPS:
-2.34
Flusso di cassa netto:
$-119.33M
1 W Prestazione:
+1.48%
1M Prestazione:
+27.10%
6M Prestazione:
+52.46%
1 anno Prestazione:
-0.96%
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Nome
Foghorn Therapeutics Inc
Settore
Industria
Telefono
617-586-3100
Indirizzo
500 TECHNOLOGY SQUARE, CAMBRIDGE
Confronta FHTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
FHTX
Foghorn Therapeutics Inc
|
6.19 | 353.40M | 34.16M | -98.43M | -119.33M | -2.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-23 | Iniziato | Citizens JMP | Mkt Outperform |
2025-01-30 | Iniziato | B. Riley Securities | Buy |
2024-09-03 | Iniziato | Jefferies | Buy |
2024-08-19 | Iniziato | Evercore ISI | Outperform |
2023-03-28 | Iniziato | BofA Securities | Buy |
2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
2021-11-22 | Iniziato | H.C. Wainwright | Buy |
2020-11-17 | Iniziato | Cowen | Outperform |
2020-11-17 | Iniziato | Goldman | Buy |
2020-11-17 | Iniziato | Morgan Stanley | Overweight |
2020-11-17 | Iniziato | Wedbush | Outperform |
Mostra tutto
Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Foghorn Therapeutics Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Autocar Professional
Trading (FHTX) With Integrated Risk Controls - news.stocktradersdaily.com
What analysts say about Foghorn Therapeutics Inc. stockAccelerated capital growth - jammulinksnews.com
What drives Foghorn Therapeutics Inc. stock pricePhenomenal capital appreciation - jammulinksnews.com
Is Foghorn Therapeutics Inc. a good long term investmentFree Stock Market Trend Analysis - jammulinksnews.com
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 0.5% – What’s Next? - Defense World
Why Foghorn Therapeutics Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser
SAIL Stock Analysis and ForecastFree Trading Psychology Coaching - Jammu Links News
What analysts say about Leonardo DRS Inc. stockMarket-beating performance - Jammu Links News
What makes Foghorn Therapeutics Inc. stock price move sharplyHigh Potential Safe Trades - Newser
How Foghorn Therapeutics Inc. stock performs during market volatilityConsistent Win Signals - Newser
(FHTX) Trading Report - news.stocktradersdaily.com
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares May Have Run Too Fast Too Soon - simplywall.st
(FHTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
112-employee biotech leaves Cambridge HQ for Watertown - The Business Journals
Foghorn Therapeutics Signs New Lease Agreement - TipRanks
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Exchange Traded Concepts LLC Grows Holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
When the Price of (FHTX) Talks, People Listen - news.stocktradersdaily.com
Foghorn Therapeutics Holds Successful Annual Meeting - TipRanks
Bank of America Corp DE Has $149,000 Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oncotherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - MENAFN.com
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - Barchart.com
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Millennium Management LLC Raises Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Acquired by Wellington Management Group LLP - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives $12.13 Consensus Target Price from Analysts - Defense World
BNP Paribas Financial Markets Makes New $61,000 Investment in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Northern Trust Corp Purchases 2,873 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Position Increased by D. E. Shaw & Co. Inc. - Defense World
Lazard Asset Management LLC Acquires New Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc Azioni (FHTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):